Welcome to our dedicated page for BNB Plus news (Ticker: BNBX), a resource for investors and traders seeking the latest updates and insights on BNB Plus stock.
BNB Plus Corp. (BNBX) generates news across both digital asset and biotechnology domains. As a Nasdaq-listed company that combines a BNB-focused digital asset treasury with nucleic acid production activities, its announcements cover developments in its BNB strategy as well as operational milestones for its LineaDNA platform.
On the digital asset side, BNB Plus issues updates on its BNB treasury holdings, private placements that support its yield-focused strategy, and tools such as the BNBX.io dashboard, which it describes as providing real-time portfolio and company metrics. These disclosures outline how the company is implementing what it calls a transparent, actively managed BNB treasury that blends DeFi and Binance-native yield opportunities.
In biotechnology and diagnostics, the company reports on LineaDNA production and customer activity through its LineaRx subsidiary. Recent news items include record LineaDNA shipments, multi-gram deliveries under supply agreements, and accelerated multi-year orders from customers in the in vitro diagnostics and biotherapeutic markets. These updates highlight the role of LineaDNA as a cell-free DNA platform used in applications such as cancer diagnostic tests.
Corporate and governance developments also feature in BNB Plus news, including its rebranding from Applied DNA Sciences, changes in board leadership, and shareholder approvals related to capital structure and warrant exercisability. Investors and observers can use this news stream to follow how the company advances its dual mandate in BNB-based treasury management and nucleic acid production.
For those tracking BNB Plus, the news page provides a centralized view of treasury updates, financing transactions, LineaDNA orders and shipments, and key corporate actions that the company discloses through press releases.
BNB Plus Corp (Nasdaq: BNBX) announced a Board-authorized review of strategic alternatives to maximize shareholder value and provided a Nasdaq listing status update. As of 1pm ET on April 18, 2026, the treasury was valued at $12.2 million, about 3.4x its market cap.
The review may include mergers, acquisitions, asset sales, capital raises and other transactions. The company implemented an active yield-generation strategy on its BNB holdings and retained Lucid Capital Markets as financial advisor. Nasdaq notified the company on March 20, 2026 of a $1.00 bid-price deficiency; a hearing has been requested.
BNB Plus (Nasdaq: BNBX) announced a European patent grant from the EPO for compositions and methods covering its chemically modified Linea RNAP, a core enzyme in the Linea™ IVT platform. The grant follows a U.S. patent in 2024 and the company plans to validate protection in key European markets through at least 2040.
The technology was acquired via the Spindle Bio acquisition in July 2023 and the company said the patent strengthens IP and potential monetization for mRNA manufacturing customers.
BNB Plus Corp (Nasdaq: BNBX) said LineaRx received two new LineaDNA orders from established genetic medicine developers, with production and shipment expected before June 2026. LineaRx recorded a $1.2 million accelerated order—the largest to date—and expects to ship over $1.5 million of LineaDNA in H1 2026, including ~8 grams this quarter.
The company implemented cost reductions delivering ~$3 million annual savings plus >$600,000 from a smaller headquarters move. BNBX also holds BNB tokens and OBNB trust units valued at >$10.7 million at $598/token as of Feb 23, 2026, reportedly more than double its market cap.
BNB Plus (Nasdaq: BNBX) appointed James Haft as an Independent Director effective February 2, 2026. Haft brings 35+ years in digital assets, blockchain infrastructure, emerging markets and capital markets, and will join the Board’s Nominating Committee to support BNB treasury operations and DeFi yield initiatives.
His background includes leadership roles at Bear Stearns, ING Barings, founding PALcapital, co-founding CryptoMondays and chairing the first publicly listed Web3 company on the Oslo Stock Exchange.
BNB Plus Corp (NASDAQ: BNBX) will present at the Digital Asset Virtual Investor Conference on January 27, 2026 at 1:00 PM EST. Chief Investment Officer Patrick Horsman, CFA, and Chairman Joshua Kruger will deliver a live presentation and be available for 1x1 meetings Jan 27–29, 2026. The event is an interactive online webcast with live Q&A and an archived replay available afterwards. Attendees are recommended to pre-register and run the system check to ensure participation. Registration and 1x1 scheduling are available via VirtualInvestorConferences.com.
BNB Plus (NASDAQ: BNBX) received a $1.2M accelerated order for LineaDNA, the largest LineaDNA order in company history.
The order accelerates an existing customer's two-year purchasing cadence into a delivery schedule expected to be completed by May 2026, and follows a prior $600,000 follow-on order from July 2025. Inclusive of the new order, the company expects to ship over $1.5M of LineaDNA to IVD and biotherapeutic customers in 1H CY2026. The announcement builds on recent fulfillment, including a LineaDNA shipment valued at over $390,000.
BNB Plus (Nasdaq: BNBX) reported successful production and shipment of the largest single LineaDNA order in company history: an approximately 5-gram delivery valued at over $390,000. The shipment was produced by subsidiary LineaRx and delivered under the company's existing bulk Supply Agreement for LineaDNA used in a cancer diagnostic test.
BNBX said it expects to fulfill additional multi-gram deliveries in the first half of calendar 2026. Management noted ongoing organizational "right sizing" while highlighting operational execution and platform resilience.
BNB Plus (Nasdaq: BNBX) announced corporate updates including a strategic addition to its BNB treasury, operational progress at its LineaRx subsidiary, and a rebrand with a new website at BNB.plus.
The company deployed approximately $3.0 million to acquire ~3,349 BNB at an average price of ~$895 per token and now holds about 18,840 BNB via direct holdings and OBNB trust units. Following a restructuring, LineaRx reduced costs and increased shipments and is expected to significantly narrow losses and approach profitability in FY26Q1 (ending Dec 31, 2025).
Applied DNA announced it will rebrand as BNB Plus Corp. (ticker BNBX) on November 17, 2025 to emphasize a yield‑optimized, BNB‑based digital asset treasury strategy leveraging the Binance ecosystem.
The company appointed Josh Kruger as Chairman of the Board; Kruger is founder of OnChain Alpha and previously served as Head of Trading at Coral Capital, which was acquired by DNA Fund in late 2024. Judy Murrah voluntarily stepped down as Chairperson and will remain a director. The firm said it has initiated a formal rebranding, including a soon‑to‑launch website at BNB.plus, and will share further updates as the transition progresses.
Applied DNA Sciences (NASDAQ: BNBX) launched BNBX.io, a real-time dashboard showing the company’s BNB treasury holdings, valuation metrics, and capitalization details.
Corporate update as of Oct 27, 2025: 4.35M shares outstanding, 23.71M fully diluted shares, ~15,553 BNB held via direct holdings and OBNB Trust units, and $8.4M cash. The company recently closed a private placement of up to $58M to support a yield-focused BNB treasury strategy and plans a weekly BNB newsletter plus additional dashboard features.